mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early treatment?

Bookmark and Share
Published: 19 Feb 2021
Views: 894
Rating:
Save
Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt Attard

Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA), Prof Stefan Oudard (Georges Pompidou Hospital, Paris, France), Prof Gerhardt Attard (University College London, London, UK) and Prof Boris Hadaschik (University of Duisburg-Essen, Essen, Germany) discuss combinations and latest data regarding non-metastatic castration-resistant prostate cancer and what does COVID-19 mean for early treatment?

They initially discuss treatment paradigms, novel drugs and new, verified treatment regimens and advances announced at the ASCO GU 2021 for nmCRPC. They then, move on to further discuss different combination therapies for patients with metastatic and non-metastatic castration-resistant prostate cancer. Within the discussion, they talk about the data from several like the ARAMIS trial, final results from ACIS and TheraP ANZUP. Prof Attard talks about PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer and Prof Oudard and Attard also discuss molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer. Dr Efstathiou and Prof Hadaschik talk about what the future looks like for these patients in terms of new treatment options.

In the end, Prof Oudard and Hadaschik also discuss how the COVID-19 pandemic has impacted early treatment of these patients and what are the consequences of it. They explain the role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer and other studies that were presented at ASCO GU 2021 regarding it.

This programme has been supported by an unrestricted educational grant from Janssen.